Imkeldi — CareFirst (Caremark)
Kaposi Sarcoma
Preferred products
- Gleevec
- imatinib mesylate
Initial criteria
- Used as subsequent therapy as a single agent or in combination with antiretroviral therapy
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months